logo-loader

A new paradigm in flexible endoscopic surgery

Last updated: 19:26 30 May 2022 AEST, First published: 19:24 30 May 2022 AEST

Creo Medical Group PLC develops and sells surgical devices for minimally invasive endoscopic surgery, mainly to remove suspected early-stage bowel cancers and also to expand cases of a narrowed oesophagus. These devices are single-use and fit onto standard flexible endoscopes. Robotic use is being added. Around 50 top-tier medical centres and 100 key opinion leaders (KOLs) around the world use Creo's products.

Its flagship multifunctional product, Speedboat Inject (Speedboat), uses dual-energy: electrical bipolar radio frequency energy for precise cutting plus super high-frequency microwave energy for controlled coagulation (to stop bleeds). It also uses an integrated needle to lift the tumour before cutting. A unique ceramic hull allows Speedboat to cut close to underlying tissues. These features boost tumour resection success rates.

The core unique selling point is that interventional endoscopists can carry out entire resections faster with one Speedboat. Competing technologies require multiple tools and exchanges which increases time and cost. Speedboat Inject and the advanced dual-energy CROMA Platform are patented, US Food and Drug Administration (FDA) approved and CE marked with a growing body of evidence (over 1000 clinical procedures) for validation.

Creo now has a major collaboration with Intuitive, the US$79bln market cap market leader in sophisticated robotic-assisted surgery. Longer-term, 3-5 years, we expected significant revenues.

 

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Parbo Resources uncovers new greenstone belt at Mount Padbury

Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone beneath previously mapped granite at the GoldenEye prospect, from just 44 metres...

5 hours, 44 minutes ago